Canagliflozin reduced the risk of the primary composite outcome (ESKD, doubling of serum creatinine, or renal or cardiovascular death) by 30% compared to placebo, with consistent effects across all prespecified subgroups [46]
Visceral fat is metabolically active and releases inflammatory signals that influence insulin resistance and cardiovascular risk
It's important to note that there is considerable individual variation in how people respond to GLP-1 therapy
Detailed results scheduled for ADA Scientific Sessions in June 2026
In our previous study (16), we discussed the potential use of GLP-1R for the diagnosis and treatment of metastatic PNETs
For mild, non-bloody diarrhoea without fever, short-course loperamide may be considered following pharmacist or clinician advice, in line with NHS self-care guidance